Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging

References

• Alikhan A, Lynch PJ, Eisen DB. (2009). Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 60:539–61.
   PubMed Web of Science ®Google Scholar
• Betti R, Rosti A, Lodi A. Bencini PL, Paparelli S, Gazzola GB, Cori P, Moroni GA, Crosti C. (1991). Effect of UVB plus tar therapy on serum levels of interleukin-2 receptors in patients with psoriasis. Clin Exp Dermatol 16:364–6.
   PubMed Web of Science ®Google Scholar
• Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Bastuji-Garin S. (2009). Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 28: ( Epub ahead of print).
   Google Scholar
• Chodorowska G, Czelej D, Niewiedzioł M. (2003). Interleukin-2 and its soluble receptor in selected drug-induced cutaneous reactions. Ann Univ Mariae Curie Sklodowska 58:7–13.
   PubMedGoogle Scholar
• Colver GB, Symons JA, Duff GW. (1989). Soluble interleukin 2 receptor in atopic eczema. BMJ 298:1426–8.
   PubMed Web of Science ®Google Scholar
• De Rie MA, Zonneveld IM, Witkamp L, Van Lier RA, Out TA, Bos JD. (1996). Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 76:357–60.
   PubMed Web of Science ®Google Scholar
• Elias AN, Goodman MM, Rohan MK. (1993). Effect of propylthiouracil and methimazole on serum levels of interleukin-2 receptors in patients with psoriasis. Int J Dermatol 32:537–40.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. (2000). Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 19:101–5.
   PubMed Web of Science ®Google Scholar
• Gebhardt M, Wenzel HC, Hipler UC, Herrmann D, Wollina U. (1997). Monitoring of serologic immune parameters in inflammatory skin diseases. Allergy 52:1087–94.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, Mouktaroudi M, Spyridaki E, Baziaka F, Pelekanou A, Giamarellou H, Stavrianeas NG. (2007). Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 156:51–6.
   PubMed Web of Science ®Google Scholar
• Halmerbauer G, Frischer T, Koller DY. (1997). Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 52:765–9.
   PubMed Web of Science ®Google Scholar
• Hurley H. (1989). Dermatologic Surgery, Principles And Practice. New York: Marcel Dekker.
   Google Scholar
• Itoh M, Goto Y, Ohta Y, Goto Y, Ohashi H. (1998). Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Rheumatol 17:26–30.
   PubMed Web of Science ®Google Scholar
• Jemec GB. (2004). Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 5:1767–70.
   PubMed Web of Science ®Google Scholar
• Kägi MK, Joller-Jemelka H, Wüthrich B. (1992). Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology 185:88–92.
   PubMed Web of Science ®Google Scholar
• Kami M, Matsumura T, Tanaka Y, Mikami Y, Miyakoshi S, Ueyama J, Morinaga S, Mori S, Machida U, Kanda Y, Chiba S, Sakamaki H, Hirai H, Muto Y. (2000). Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leuk Lymphoma 38:533–40.
   PubMed Web of Science ®Google Scholar
• Kapp A, Piskorski A, Schöpf E. (1988). Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 119:707–10.
   PubMed Web of Science ®Google Scholar
• Karvonen SL, Räsänen L, Soppi E. Hyöty H, Lehtinen M, Reunala T. (1995). Increased chemiluminescence of whole blood and normal T-lymphocyte subsets in severe nodular acne and acne fulminans. Acta Derm Venereol 75:1–5.
   PubMed Web of Science ®Google Scholar
• Kemmett D, Symons JA, Colver GB, Duff GW. (1990). Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement. Acta Derm Venereol 70:264–6.
   PubMed Web of Science ®Google Scholar
• Korobowicz A. (2006). [Biology of tumor necrosis factor type alpha (TNF-alpha)]. Pol Merkur Lekarski 21:358–61.
   PubMedGoogle Scholar
• Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J, Zouboulis CC. (2008). What causes hidradenitis suppurativa? Exp Dermatol 17:455–6.
   PubMed Web of Science ®Google Scholar
• Lapins J, Asman B, Gustafsson A, Bergström K, Emtestam L. (2001). Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm Venereol 81:96–9.
   PubMed Web of Science ®Google Scholar
• Leonardi S, Marchese G, Rotolo N, Miraglia Del Giudice M, La Rosa M. 2004. Cyclosporin is safe and effective in severe atopic dermatitis of childhood. Report of three cases. Minerva Pediatr 56:231–7.
   PubMedGoogle Scholar
• Matsumoto T, Furukawa A, Sumiyoshi Y, Akiyama KY, Kanayama HO, Kagawa S. (1998). Serum levels of soluble interleukin-2 receptor in renal cell carcinoma. Urology 51:145–9.
   PubMed Web of Science ®Google Scholar
• Nakata B, Chung KH, Kato Y, Yamashita Y, Inui A, Arimoto Y, Maeda K, Onoda N, Sawada T, Sowa M. (1998). Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer 77:1820–4.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Iijima K, Chizuka A. (2001). A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Eur J Haematol 66:24–30.
   PubMed Web of Science ®Google Scholar
• O’Loughlin S, Woods R, Kirke PN, Shanahan F, Byrne A, Drury MI. (1988). Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Arch Dermatol 124:1043–6.
   PubMedGoogle Scholar
• Plewig G, Steger M. (1989). Acne inversa. In: Marks R, Plewig G, editors. Acne and Related Disorders. London: Martin Dunitz Ltd. p. 345–7.
   Google Scholar
• Poli F, Jemec GB, Revuz J. (2006). Clinical presentation. In: Jemec GB, Revuz J, Leyden J, editors. Hidradenitis Suppurativa. Heidelberg: Springer. p. 11–24.
   Google Scholar
• Revuz J. (2007). Modifications et mode d’emploi du score de Sartorius pour évaluer la gravité de l’hidradénite suppurée. Ann Dermatol Venereol 134:173–80.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. (1985). Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–7.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Lapins J, Emtestam L, Jemec GB. (2003). Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 149:211–13.
   PubMed Web of Science ®Google Scholar
• Sellheyer K, Krahl D. (2005). ‘Hidradenitis suppurativa’ is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 44:535–40.
   PubMed Web of Science ®Google Scholar
• Serhat Inaloz H, Ozturk S, Akcali C, Kirtak N, Tarakcioglu M. (2008). Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. J Dermatol 35:276–82.
   PubMed Web of Science ®Google Scholar
• Shohat M, Mimouni D, Ben-Amitai D, Sredni B, Sredni D, Shohat B, David M. (2005). In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101. Clin Exp Dermatol 30:432–4.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Riccieri V, Benfari G, Scillone M, Taccari E. (2001). Soluble interleukin-2 receptor in Sjögren’s syndrome: relation to main serum immunological and immunohistochemical parameters. Clin Rheumatol 20:319–23.
   PubMed Web of Science ®Google Scholar
• Suenaga Y, Yasuda M, Yamamoto M. Nonaka S, Wada T, Shiokawa S, Nobunaga M. (1998). Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis. Clin Rheumatol 17:311–17.
   PubMed Web of Science ®Google Scholar
• Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, Brunin F, Fridman WH, Rodriguez J. (2001). Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 357:1263–4.
   PubMed Web of Science ®Google Scholar
• Valsecchi R, Imberti G, Martino D, Cainelli T. (1992). Alopecia areata and interleukin-2 receptor. Dermatology 184:126–8.
   PubMed Web of Science ®Google Scholar
• von der Werth JM, Jemec GB. (2001). Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 144:809–13.
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams JT, Bigler RD, Wasik MA. (1998). Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 38:207–20.
   PubMed Web of Science ®Google Scholar
• Wortsman X, Revuz J, Jemec GB. (2009). Lymph nodes in hidradenitis suppurativa. Dermatology (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Zillikens D, Ambach A, Zentner A. Dummer R, Schüssler M, Burg G, Bröcker EB. (1993). Evidence for cell-mediated immune mechanisms in the pathology of pemphigus. Br J Dermatol 128:636–43.
   PubMed Web of Science ®Google Scholar